(IONS) Ionis Pharmaceuticals - Ratings and Ratios

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a commercial-stage biotechnology company specializing in RNA-targeted therapeutics. The company has established a robust portfolio addressing rare and severe diseases. Its approved products include WAYLIVRA for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy; TEGSEDI for hereditary transthyretin amyloidosis (ATTR); and SPINRAZA for spinal muscular atrophy (SMA). The pipeline includes late-stage candidates such as olezarsen for hypertriglyceridemia and donidalorsen for hereditary angioedema, alongside earlier-stage programs targeting Alexander disease and other rare genetic disorders. Ionis leverages its antisense technology platform to develop precision medicines, collaborating with major pharmaceutical companies to expand its therapeutic reach. The company was founded in 1989 and is headquartered in Carlsbad, California.

The company’s pipeline includes multiple assets in advanced clinical stages. Eplontersen targets transthyretin-related amyloidosis, while pelacarsen aims to reduce lipoprotein(a) levels. Bepirovirsen is under investigation for chronic hepatitis B, and sefaxersen focuses on complement-mediated diseases. These programs highlight Ionis’s commitment to addressing unmet medical needs through innovative RNA-targeting approaches.

Ionis has established strategic collaborations with industry leaders such as Biogen, GSK, AstraZeneca, Novartis, and Roche, enhancing its research and development capabilities. These partnerships underscore its role as a key player in the biotechnology sector, with a focus on advancing RNA-based therapies for complex diseases.

From a financial perspective, Ionis Pharmaceuticals operates with a market capitalization of $4.5 billion. The stock trades with a forward P/E ratio of 90.91 and a price-to-book ratio of 7.67. The average daily trading volume is approximately 1.9 million shares, reflecting moderate liquidity. The stock’s technical indicators show a 20-day moving average of $28.40 and a 50-day average of $30.91, with a 200-day average of $37.82. The average true range (ATR) is 1.48, indicating manageable volatility.